Enliven Therapeutics
ELVN
63 hedge funds and large institutions have $798M invested in Enliven Therapeutics in 2023 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 19 increasing their positions, 10 reducing their positions, and 7 closing their positions.
257% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 7
90% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 10
40% more funds holding
Funds holding: 45 → 63 (+18)
9% more capital invested
Capital invested by funds: $735M → $798M (+$63M)
14% less funds holding in top 10
Funds holding in top 10: 7 → 6 (-1)
416.92% less ownership
Funds ownership: 512.07% → 95.15% (-417%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$30.6M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$20M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$16.9M |
| 4 |
CC
Commodore Capital
New York
|
+$12.5M |
| 5 |
State Street
Boston,
Massachusetts
|
+$9.23M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
|
-$4.67M |
| 2 |
BCM
BML Capital Management
Zionsville,
Indiana
|
-$2.79M |
| 3 |
LGM
Logos Global Management
San Francisco,
California
|
-$1.9M |
| 4 |
Millennium Management
New York
|
-$1.03M |
| 5 |
Renaissance Technologies
New York
|
-$689K |
ELVN Hedge Fund Activity: Q2 2023 in Review
63 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Enliven Therapeutics (ELVN) for Q2 2023, worth a combined $798M — up 8.6% from $735M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new ELVN positions and 7 closed out — a net gain of 18 holders — while 19 added to existing stakes and 10 trimmed.
The largest buyer was BlackRock, adding an estimated $30.6M. The largest seller was Janus Henderson Group, cutting an estimated $4.67M.
- 63 institutional investors held Enliven Therapeutics (ELVN) as of Q2 2023, up from 45 in Q1 2023.
- Funds reported $798M of Enliven Therapeutics stock for Q2 2023, up 8.6% quarter-over-quarter.
- 25 funds opened new Enliven Therapeutics positions in Q2 2023 and 7 closed out, a net change of +18 holders.
- The largest Enliven Therapeutics buyer in Q2 2023 was BlackRock, an estimated $30.6M added.
- The largest Enliven Therapeutics seller in Q2 2023 was Janus Henderson Group, an estimated $4.67M sold.
Based on aggregated 13F filings for Q2 2023.